Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BB I haven't sent an email in a while with a request for a reply so don't know. Maybe the company is in a quiet period and is up to something positive. If so JT won't appear at the Cantor conference.....we can only hope...
ILT, hope you don't mind but I will forward the article you posted to Elisabeth and request she forward to jt and the bod. Let's see if her reply has a hint of possibility that Amarin is considering this approach.
ILT, thanks that article was an eye opener. I hope you're right and that amarin has been discussing this option it certainly would provide for a brighter future for vascepa and share price.
ILT,
Please consider forwarding your post to jt and BOD. The article provides the perfect solution for Amarin's future growth. Thanks
sleven, I don't know the answer to your idea but I know one thing Amarin doesn't have the time to start another marine trial for a different application. If jt et al doesn't do something to turn around this current situation the stock will continue to drift lower and that ain't a good thing!
Yes, news hit the tape Sat. GILD is in the mkt shopping to expand their drug offerings, they've made several acquisition this year. There's still hope for amarin IF they get their act together.
lbl, I love your warped sense of humor...lol
gary, in theory that sounds like an option that would make sense maybe make the EU and ROW a subsidiary of the parent company the parent company remains in the USA with ownership of the vascepa patents and create a division in the other countries that would sell the branded vascepa and pay a royalty to the parent which would remain here in the states OR how about the hqtrs in Ireland they would own the distribution rights to all other countries outside of USA???? Then vascepa would have a global presence...
Just thinking out loud....
insync, if I'm not mistaken 8 or one of our legal team ppl suggested that the induced infringement case be filed asap before the actual launch by the generics. I'm just a layman regarding anything legal.
If and when jt decides to go the generic route what's the procedure with the FDA and how long would it take for gv to actually hit the shelves???
Let's hope for the shareholders sake jt comes to his senses and drives the company forward rather than the courts deciding the fate of AMRN!! Honestly, if jt won't step aside maybe someone could convince him to take on a co-ceo person with experience in turn arounds.
insync, I recall jt talking about the GV idea on cc and in the 10Q. Do you know for a fact that Amarin is working on that concept? If so it would be awesome to get a jump start on the bad guys here in the USA and have brand name in the EU and ROW. So what if profit margins are lower here, the sales of vascepa priced accordingly in EU etc would make up for lower margins state side.
sts, they didn't read the briefs, very bad vibes when Dyk didn't know Du was a woman. Flaming libs didn't give a hoot about Amarin and the yrs of research and money that was spent getting vascepa to the point where they can finally market the drug with great credentials. In their heads, the good guys are the generics, free medicine for all, free education blah blah.
Here you go! it was sent on July 14, 2020 #286039
jwjones62
jwjones62 Tuesday, 07/14/20 03:47:03 PM
Re: None 0
Post #
286039
of 298471
I sent the following email to John Thero and Elizabeth..
Good afternoon John,
I am writing as a shareholder and a big believer in Vascepa and its enormous potential to help so many people. I have grown increasingly frustrated with the performance in the execution of the commercialization of Vascepa by Amarin Management. This has been highlighted by the impractical Nevada court filing and allowing the court case to proceed without setting with H&R. This decision may be a fatal blow to AMRN and its shareholders. We are all essentially holding our breath and praying that Mr. Singer can win the appeal. It should never have come to this.
I have 2 areas of concern that I would like addressed.
1.) After suffering the enormous judicial setback which resulted in crippling the commercialization efforts and destroying shareholder value in Amarin stock, please explain how Amarin chose to file another patent infringement suit in NEVADA of all places? It also appears the suit was also assigned to Judge Miranda Du. Please share some insight as to how the Nevada courts could once again be chosen to file a secondr court case, since the first selection devastated your loyal shareholders. Don't you have a fiduciary responsibility to preserve and increase shareholder value?
2.) Why haven't the voting results or any update from the annual shareholder meeting been publicized?
I am eagerly awaiting your response.
I wonder if JT was referring to the Baker Bros. when he referred to "the investors" and not the people on the IHub message board when he wrote his now infamous email reply that was posted.
Think about it as a very real possibility.
postes, sorry, do you recall exactly who JT's email was address to?
Marjac,
Can we do anything with JT's email response to postes #286762
Clearly JT placed blame on the investor's who have expressed what the settlement terms would be acceptable to them and not consult with the BOD!
ccc: post #286762 thero's email to postes,
Lizzy...here is What JT wrote
Your first judgment assumes that a settlement was available on terms that you would not have been similarly disappointing. We listened to input from many investors over the past several years. Such input included suggestions on what would be settlement terms that they would accept. The settlement terms that were suggested by investors were not available and we emphasized for many years that the courts can be unpredictable in such matters (which the ANDA filers knew as well and it cost them little to pursue this matter). The confidential nature of such court overseen settlement discussions prevent disclosure of further details.
Private Reply | Keep | Public Reply | View Replies (1) | Mark as Last Read[color=red][/color]
© 2020 InvestorsHub.com, Inc.
About
About Us
Terms of Service
Cookie and Privacy Policy
Advertise With Us
Data Accreditations
Disclaimer
Help
FAQ
Handbook
Q&A Forum
Contact Us
Tutorials
Educational
Educational Channel
Stock Market 101
Educational Videos
Investor Help Forum
More
Corporate Solutions
iHub on Facebook
iHub on Twitter
iHub iPhone/iPad App
iHub Android App
iHub NewsWire
You are lizzy241 on WEB9
Consent Preferences
Yup. As stan said to olie "well here's another fine mess you've gotten us into". Take your pick which one is stan and which is olie! Thero or Kennedy!
I know that, but why not deal w someone in nj or nyc? Why ca.? Is jt tied at the hip to kennedy? Hopefully we can find a way to oust them from their current positions. I understand you may not agree but we can't let jt et al gia in the EU.
momo, thanks, FYI I made a call to the Baker Bros. fund. A real person answered, he claims he'll pass along my contact info to the analyst. We'll see if I actually receive a call back.
raf, why would Amarin deal with an attorney who lives on the west coast???
momo, is that what Raf was referencing re Kennedy's linkedin page?
No title for the article? If it was published in 2011 that was before Du was appointed by OBAMA and before the courts decided to disperse the patent cases to the newbies in the 9th district. Someone posted an article recently about how the patent judges get paid according to the number of patent cases heard, which is a disgrace in and of its self.
raf, what am I missing re the NV connection. reviewed Kennedy's linkedin page, nothing caught my eye???
tuca, do you know how TRIL ousted their old management team. What process did they use to accomplish that action???
BB, kindly point to the changes. Thanks
Hikma's full press release.
Hikma receives favourable court ruling for its generic Vascepa®
Press Release
London, September 3, 2020 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical
company, announces that the US Court of Appeals for the Federal Circuit today upheld a ruling by the
US District Court for the District of Nevada finding that Hikma’s generic version of Vascepa®1
(icosapent
ethyl) 1gm does not infringe any valid claim of six key Amarin-owned patents. Hikma received FDA
approval for the product in May 2020 and is working towards a launch.
Vascepa®
is a prescription medicine that is indicated, in part, as an adjunct to diet to reduce triglyceride
levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. According to IQVIA, US sales of
Vascepa® were approximately $1.1 billion in the 12 months ending July 2020.
“We are very pleased with the Federal Circuit’s swift decision and to be one step closer to launching a
generic version of this important medicine for US patients and healthcare providers, helping us to
continue putting better health, within reach, every day,” said Brian Hoffmann, President of Hikma
Generics. “Today’s decision demonstrates Hikma’s ability to successfully challenge patents on important
medicines and to provide value to our customers and millions of patients across the United States.”
BB is this the Hikma announcement? If so, it's still listed on the news link.
/www.hikma.com/media/2836/vascepa-statement-september-2020-vfinal.pdf
lrich, very sad situation we find ourselves in. I'm in shock that a company can have the greatest product ever discovered and unless the current management understands that they MUST step down and let their baby go we are screwed. I'm talking from experience I could write a book about my personal experience with starting a company from an idea to a great cutting edge medical software company then to be blindsided from the passing of the CEO, consequently being lead by a very tech savvy partner but with zero personality who continued to take a salary as our revenues declined. Puff gone!!!
lrich, spot on with your response to jasb.
Do we as common shareholders have any recourse? Other than waiting for Marjac to file a derivative lawsuit, but people who own the common stock will not be compensated in any way with a derivative suit so what's the alternative?
I agree with everyone on this board that jt should be forced to resign. Unfortunately, as a common stockholder we are last in line for any representation to voice our opinion. We need someone such as a bondholder or a stakeholder who has voting rights to opine on the current BOD situation and get them to move their asses to sell the company. We need a proactive investor with a legal say in how the company moves forward.
I'm very afraid that if jt and the BOD decide to GIA in the EU and ROW the company will go bankrupt. I realize it's a pretty bold statement but it's a reality we must consider.
mark, more like steve giardino, scum of the earth
cbb, typo...the sofinnova phone # is 650-681-8420.
I'll attempt a call to inquire as to the best way to reach Dr. Ekman.
bidmark, yes about singer and en banc, he lost.
We are in a NO win situation until the freakin company is sold.
Yeah, let's hear it for louieblouie!!!
cbb,
yes indeed they had a shot but JT blew it. Rather than JT and BOD continuing to wait for the next event to try to increase the value of the BO which is clearly how they've approached the destiny of the company. They should be been satisfied after Reduct It success and rang the register, they could have made some kind of settlement with GV during buyout negotiations.
Does anyone on this board have an inside connection to the Baker Bros. to have a sit down, maybe get some further insight into how the company is currently thinking????
cbb,
Why not sell the company to Amazon!!
cruyff:
I can provide a very good example of an FDA approved drug that now sells on Amazon in a smaller size bottle direct to consumers without a script from the doc. If anyone cares to research you'll find an interesting correlation between your idea and NovaBay, symbol (NBY). The product is called Avenova.
I am not promoting the company or product merely stating facts. The company has an excellent eyelid cleanser spray that was only available from an optometrist. They changed their marketing strategy and went direct to consumer thus bypassing the eye doc. It was a little confusing at first, I called the company to ask how they can do that, their response was to simply change the bottle size to a smaller one that doesn't require a script. It's so much easier to obtain the product rather than going to the eye doc.
cbb, thank you I have a good feeling about your source and approx value being btw $13-$20.
cbb, another excellent explanation of our current situation. Please consider forwarding your posts to Elisabeth or JT. Thanks
cbb, well stated, you're right on the mark!